Safety Study of KPT-330 (Selinexor) in Patients With Advanced or Metastatic Solid Tumor Cancer

ABSTRACT: Phase 1 study to evaluate the safety and tolerability of selinexor and determine the Recommended Phase 2 Dose (RP2D) of selinexor for advanced or metastatic solid tumor malignancies.

DISEASE(S): Adenocarcinoma,Solid Tumor,Melanoma,Colorectal Cancer,Neoplasms

PROVIDER: 2126069 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR